Clinical Trials Logo
  1. Home
  2. Radiotherapy Side Effect
  3. NCT03109080

Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) — RadioPARP  

Radiotherapy Side Effect Clinical Trial

Official title:
A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease

Clinical Trial Summary

A Phase I of Olaparib with Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (triple negative breast cancer) or Patient With Operated TNBC with Residual Disease.

Clinical Trial Description

Open label phase I, dose escalation trial for patients with triple negative inflammatory, loco-regional advanced or metastatic breast cancer either inoperable after neoadjuvant chemotherapy or operated with residual disease (after neoadjuvant chemotherapy). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03109080
Study type Interventional
Source Institut Curie
Contact
Status Completed
Phase Phase 1
Start date July 24, 2017
Completion date November 29, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT05543239 - Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Radiotherapy-Related Neuropathic Pain N/A
Terminated NCT04535908 - Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older. N/A
Recruiting NCT04115267 - Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Recruiting NCT05820633 - Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer. N/A
Completed NCT05880446 - PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ) N/A
Recruiting NCT05724004 - Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) N/A
Recruiting NCT04612907 - Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer N/A
Recruiting NCT05762900 - Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients Phase 2
Recruiting NCT03613506 - The Role and Intervention of TGF-β in Abdominal Radiation Injury Phase 2
Completed NCT06353724 - Comparison Between the Effect of Using Conventional and Digital Oral Positional Radiation Stent N/A
Not yet recruiting NCT05548504 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Phase 2
Recruiting NCT05224297 - Patient Experience Data in Radiation Oncology
Recruiting NCT05776147 - Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
Completed NCT04842409 - Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery
Recruiting NCT03742687 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC N/A
Not yet recruiting NCT05614700 - Prostate Reirradiation Toxicity Outcomes Feasibility Study N/A
Completed NCT04027543 - Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）
Recruiting NCT05354596 - A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY). N/A
Recruiting NCT03378856 - Evaluation of Technological Innovation in Radiotherapy